查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1803083

2032 年预防医学市场预测：按服务类型、技术、交付模式、应用、最终用户和地区进行的全球分析

Preventive Medicine Market Forecasts to 2032 - Global Analysis By Service Type, Technology, Mode of Delivery, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球预防医学市场预计在 2025 年达到 4,515.9 亿美元，到 2032 年将达到 9,258.2 亿美元，预测期内的复合年增长率为 10.8%。

预防医学是医疗保健领域的一部分，旨在透过预防疾病、伤害和残疾来保护、促进和维护健康。预防性医疗保健包括改变生活方式、医疗干预、定期体检和接种疫苗，以降低风险并及早发现潜在的健康问题。预防性医疗保健注重主动护理，能够促进整体健康，最大限度地降低医疗成本，并在个人、社区和人口层面支持更健康的生活方式。

慢性病增多

心臟病、肥胖症和糖尿病等慢性疾病的流行刺激了预防性医疗保健的需求。由于许多此类疾病与生活方式选择有关，早期疗育被视为降低长期风险的可行解决方案。医疗保健系统和政策制定者正将重点转向预防，以控製成本并改善整体健康。宣传宣传活动和公众宣导活动鼓励人们采取更健康的生活方式并定期进行体检。科学研究不断检验预防策略在降低发病率的有效性。因此，慢性病趋势是预防性医疗保健产业扩张的主要催化剂。

缺乏经济奖励

由于医疗体系内部的经济奖励错位，预防保健往往难以扎根。许多支付结构仍然优先治疗而非预防，导致早期照护模式的投资对医疗服务提供者缺乏吸引力。医生可能无法因提供预防服务而获得报酬，这限制了他们融入常规医疗实践。保险单通常不涵盖健康计划和筛检，这限制了许多患者的就医机会。长期储蓄与短期经济回报之间的这种脱节，在市场推广中造成了阻力。如果不改变报销和奖励框架，预防保健将难以有效扩大规模。

与数位健康和​​人工智慧的融合

预防医学与数位工具和人工智慧的融合，为个人化医疗开闢了新的途径。健身追踪器和健康应用程式等设备使用户能够即时监测自身健康状况，从而促进主动健康管理。人工智慧演算法能够分析数据，发现疾病的早期征兆，并根据个人需求量身定制干预措施。这些技术也使预防服务更具可扩展性和可近性，尤其是在医疗基础设施有限的地区。随着数位医疗的普及，它支持更聪明、更有效率的疾病预防方法。这些技术的协同作用正在重塑预防性医疗的提供和体验方式。

资料隐私与网路安全风险

随着预防性医疗保健越来越依赖数位平台，人们对资料安全和隐私的担忧也日益凸显。透过应用程式和远端监控系统收集的健康资料容易受到骇客攻击和未授权存取。现有法规往往落后于技术创新的步伐，导致用户面临潜在的滥用风险。敏感资讯的外洩会削弱信任，并减缓数位健康解决方案的普及。规模较小的供应商可能缺乏实施强大网路安全通讯协定的资源，从而增加其脆弱性。

COVID-19的影响：

由于医疗系统将资源重新用于疫情应对，新冠疫情的爆发暂时阻碍了预防医学的发展。筛检和体检等非紧急服务被推迟，影响了早期诊断和介入工作。然而，这场危机凸显了主动医疗管理和系统性韧性的价值。疫情期间远端医疗的迅速普及，为远距医疗服务开闢了新的途径。随着世界经济復苏，这场疫情激发了以预防为导向的思维模式，并重新运作了市场投资和创新。

预计疫苗接种和疫苗接种服务部门将成为预测期内最大的部门

在社会日益关注疾病预防和加强全球卫生计画的推动下，免疫接种和疫苗接种服务领域预计将在预测期内占据最大的市场占有率。 mRNA递送、病毒载体系统和标靶免疫学等疫苗技术正在提高疫苗效力并缩短研发週期。个人化物流、人工智慧物流和免疫资讯学等趋势正在重塑疫苗格局。近期的创新包括广谱频谱疫苗、先进的疟疾和呼吸道合胞病毒（RSV）製剂以及改进的供应链基础设施。政府支持和与数位平台的整合正在加速疫苗的普及，使疫苗成为现代预防医学的基石。

预计家庭医疗保健领域在预测期内将实现最高复合年增长率

预计家庭医疗保健领域将在预测期内实现最高成长率，这得益于人口老化和慢性病发病率上升背景下对平价便捷医疗服务的需求不断增长。智慧型穿戴装置、虚拟咨询和远端监控工具等技术进步正在改善早期发现和持续支援。最近的进展包括人工智慧驱动的健康追踪、用户友好的行动平台以及无缝的数据整合。新兴趋势着重于客製化照护计画、家庭看护者参与和基于结果的医疗保健。主动式居家照护的演变正在再形成预防性医疗保健，并将其范围扩展到传统临床环境之外。

占比最大的地区：

预计亚太地区将在预测期内占据最大的市场占有率，这得益于文明病的增加、人口结构变化以及公众健康意识的不断增强。基于人工智慧的诊断、穿戴式监测设备和数位健康平台等技术创新正在增强早期疗育和个人化治疗。最近的进展包括基于应用程式的健康追踪、数据主导的风险评估和可扩展的预防性医疗保健模式。主要趋势包括远端医疗服务的扩展、雇主资助的健康计划以及以结果为导向的医疗服务。政府的支持性政策和对医疗基础设施不断增加的投资，正在推动该地区朝着更预防性和以患者为中心的方向发展。

复合年增长率最高的地区：

在预测期内，由于人口老化、慢性病增多以及完善的医疗保健体系，北美预计将呈现最高的复合年增长率。智慧诊断、穿戴式健康监测器和人工智慧筛检等先进技术正在增强早期疗育和个人化治疗。值得关注的发展包括雇主主导的倡议、基于结果的报销模式以及预防保健保险覆盖范围的扩大。关键亮点包括远端医疗、行动医疗解决方案和数据主导风险预测的兴起。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球预防医学市场（依服务类型）

  • 健康筛检和风险评估
  • 免疫接种及疫苗接种服务
  • 生活方式和健康计划
  • 基因检测与个人化医疗
  • 数位预防解决方案
  • 其他服务类型

6. 全球预防医学市场（依技术）

  • 早期检测与筛检技术
  • 远端监控设备
  • 慢病管理平台
  • 预测分析和人工智慧工具

7. 全球预防医学市场（依交付类型）

  • 现场服务
  • 远端医疗和远距护理服务
  • 行动医疗应用程式

8. 全球预防医学市场（按应用）

  • 心血管疾病
  • 癌症
  • 糖尿病
  • 感染疾病
  • 呼吸系统疾病
  • 神经系统疾病
  • 其他用途

9. 全球预防医学市场（依最终用户）

  • 医院和诊所
  • 诊断中心
  • 企业和职场健康服务提供者
  • 家庭医疗保健
  • 政府和公共卫生机构
  • 其他最终用户

第 10 章全球预防医学市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Novo Nordisk
  • Medtronic plc
  • Eli Lilly and Company
  • Philips Healthcare
  • Quanterix Corporation
  • GE HealthCare
  • US Preventive Medicine, Inc.
  • Siemens Healthineers
  • Cancer Prevention Pharmaceuticals
  • Johnson & Johnson
  • Preventive Medical Health Care
  • Abbott Laboratories
  • Phoenix Medicine
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Sanofi
  • Merck & Co., Inc.
Product Code: SMRC30608

According to Stratistics MRC, the Global Preventive Medicine Market is accounted for $451.59 billion in 2025 and is expected to reach $925.82 billion by 2032 growing at a CAGR of 10.8% during the forecast period. Preventive medicine is a healthcare discipline dedicated to safeguarding, enhancing, and sustaining health by avoiding diseases, injuries, and disabilities before they arise. It includes lifestyle modifications, medical interventions, regular screenings, and immunizations to lower risks and identify potential health problems early. By focusing on proactive care, preventive medicine promotes overall well-being, minimizes healthcare expenses, and supports healthier lives at individual, community, and population scales.

Market Dynamics:

Driver:

Rising Incidence of Chronic Diseases

The growing prevalence of chronic illnesses like heart disease, obesity, and diabetes is fueling demand for preventive healthcare approaches. Since many of these conditions are linked to lifestyle choices, early intervention is increasingly seen as a practical solution to reduce long-term risks. Health systems and policymakers are shifting focus toward prevention to manage costs and improve overall well-being. Awareness campaigns and public education are encouraging individuals to adopt healthier habits and seek regular checkups. Scientific research continues to validate the effectiveness of preventive strategies in lowering disease rates. As a result, chronic disease trends are acting as a major catalyst for the expansion of the preventive medicine industry.

Restraint:

Lack of Aligned Financial Incentives

Preventive care often struggles to gain traction due to misaligned economic incentives within healthcare systems. Many payment structures still prioritize treatment over prevention, making it less attractive for providers to invest in early care models. Physicians may not be rewarded for offering preventive services, which limits their integration into routine practice. Insurance policies frequently exclude coverage for wellness programs and screenings, reducing access for many patients. This cut off between long-term savings and short-term financial returns creates friction in market adoption. Without changes to reimbursement and incentive frameworks, preventive medicine faces challenges in scaling effectively.

Opportunity:

Integration with Digital Health and AI

The fusion of preventive medicine with digital tools and artificial intelligence is opening new avenues for personalized healthcare. Devices like fitness trackers and health apps allow users to monitor their well-being in real time, promoting proactive health management. AI algorithms can analyze data to detect early signs of illness and tailor interventions to individual needs. These technologies also make preventive services more scalable and accessible, especially in areas with limited medical infrastructure. As digital health becomes more widespread, it supports smarter, more efficient approaches to disease prevention. This technological synergy is reshaping how preventive care is delivered and experienced.

Threat:

Data privacy and cybersecurity risks

As preventive medicine increasingly relies on digital platforms, concerns about data security and privacy are becoming more pronounced. Health data collected through apps and remote monitoring systems is susceptible to hacking and unauthorized access. Existing regulations often lag behind the pace of innovation, leaving users exposed to potential misuse. A breach of sensitive information can undermine trust and slow adoption of digital health solutions. Smaller providers may lack the resources to implement strong cybersecurity protocols, increasing vulnerability.

Covid-19 Impact:

The onset of COVID-19 temporarily stalled progress in preventive medicine, as healthcare systems redirected resources to manage the pandemic. Non-urgent services like screenings and wellness visits were delayed, affecting early diagnosis and intervention efforts. However, the crisis underscored the value of proactive health management and system resilience. The rapid adoption of telehealth during lockdowns created new pathways for delivering care remotely. As the world recovers, the pandemic has catalyzed a more prevention-oriented mindset, reinvigorating investment and innovation in the market.

The immunization & vaccination services segment is expected to be the largest during the forecast period

The immunization & vaccination services segment is expected to account for the largest market share during the forecast period, driven by increasing public focus on disease prevention and strengthened global health programs. Vaccine technologies such as mRNA delivery, viral vector systems, and targeted immunology are improving effectiveness and development timelines. Trends like customized immunization, AI-powered logistics, and immuno-informatics are reshaping the landscape. Recent innovations include broad-spectrum flu vaccines, advanced malaria and RSV formulations, and improved supply chain infrastructure. Support from governments and integration with digital platforms are accelerating uptake, positioning vaccines as a cornerstone of modern preventive medicine.

The home healthcare segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home healthcare segment is predicted to witness the highest growth rate, due to increasing demand for affordable, accessible care amid growing elderly populations and chronic illness rates. Advancements in technology such as smart wearables, virtual consultations, and remote monitoring tools are improving early detection and continuous support. Recent progress includes AI-enabled health tracking, user-friendly mobile platforms, and seamless data integration. Emerging trends emphasize customized care plans, family caregiver engagement, and outcome-based healthcare. This evolution toward proactive, home-based services is reshaping preventive medicine and expanding its reach beyond traditional clinical environments.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising lifestyle-related illnesses, demographic shifts, and growing public health consciousness. Innovations in technology such as AI-driven diagnostics, wearable monitoring devices, and digital health platforms are enhancing early intervention and personalized treatment. Recent advancements include app-based wellness tracking, data-driven risk assessments, and scalable preventive care models. Key trends involve expanding telehealth services, employer-sponsored wellness programs, and outcome-focused healthcare delivery. Supportive government policies and increased investment in healthcare infrastructure are propelling the region toward a more preventive and patient-centric approach.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by an aging population, rising chronic conditions, and well-established healthcare systems. Advanced technologies such as smart diagnostics, wearable health monitors, and AI-enabled screening are enhancing early intervention and personalized treatment. Notable developments include employer-led wellness initiatives, outcome-based reimbursement models, and expanded insurance coverage for preventive care. Key trends highlight the rise of telemedicine, mobile health solutions, and data-driven risk prediction.

Key players in the market

Some of the key players in Preventive Medicine Market include Novo Nordisk, Medtronic plc, Eli Lilly and Company, Philips Healthcare, Quanterix Corporation, GE HealthCare, U.S. Preventive Medicine, Inc., Siemens Healthineers, Cancer Prevention Pharmaceuticals, Johnson & Johnson, Preventive Medical Health Care, Abbott Laboratories, Phoenix Medicine, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi, and Merck & Co., Inc.

Key Developments:

In July 2025, Eli Lilly and Company announced the successful completion of its acquisition of Verve Therapeutics, Inc., Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment.

In May 2025, Septerna, Inc. and Novo Nordisk announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases. The companies will initially commence four development programmes for potential small molecule therapies directed to one or more select G protein-coupled receptor (GPCR) targets, including the GLP-1, GIP and glucagon receptors.

In April 2025, Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump. Medtronic plc announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration with a continuous glucose monitoring (CGM) sensor based on Abbott's most advanced CGM platform.

Service Types Covered:

  • Health Screenings & Risk Assessments
  • Immunization & Vaccination Services
  • Lifestyle & Wellness Programs
  • Genetic Testing & Personalized Medicine
  • Digital Preventive Solutions
  • Other Service Types

Technologies Covered:

  • Early Detection & Screening Technologies
  • Remote Monitoring Devices
  • Chronic Disease Management Platforms
  • Predictive Analytics & AI Tools

Mode of Deliveries Covered:

  • In-Person Services
  • Telemedicine & Remote Care Services
  • Mobile Health Applications

Applications Covered:

  • Cardiovascular Diseases
  • Cancer
  • Diabetes
  • Infectious Diseases
  • Respiratory Diseases
  • Neurological Disorders
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Centers
  • Corporate & Workplace Wellness Providers
  • Home Healthcare
  • Government & Public Health Agencies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Preventive Medicine Market, By Service Type

  • 5.1 Introduction
  • 5.2 Health Screenings & Risk Assessments
  • 5.3 Immunization & Vaccination Services
  • 5.4 Lifestyle & Wellness Programs
  • 5.5 Genetic Testing & Personalized Medicine
  • 5.6 Digital Preventive Solutions
  • 5.7 Other Service Types

6 Global Preventive Medicine Market, By Technology

  • 6.1 Introduction
  • 6.2 Early Detection & Screening Technologies
  • 6.3 Remote Monitoring Devices
  • 6.4 Chronic Disease Management Platforms
  • 6.5 Predictive Analytics & AI Tools

7 Global Preventive Medicine Market, By Mode of Delivery

  • 7.1 Introduction
  • 7.2 In-Person Services
  • 7.3 Telemedicine & Remote Care Services
  • 7.4 Mobile Health Applications

8 Global Preventive Medicine Market, By Application

  • 8.1 Introduction
  • 8.2 Cardiovascular Diseases
  • 8.3 Cancer
  • 8.4 Diabetes
  • 8.5 Infectious Diseases
  • 8.6 Respiratory Diseases
  • 8.7 Neurological Disorders
  • 8.8 Other Applications

9 Global Preventive Medicine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Centers
  • 9.4 Corporate & Workplace Wellness Providers
  • 9.5 Home Healthcare
  • 9.6 Government & Public Health Agencies
  • 9.7 Other End Users

10 Global Preventive Medicine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Novo Nordisk
  • 12.2 Medtronic plc
  • 12.3 Eli Lilly and Company
  • 12.4 Philips Healthcare
  • 12.5 Quanterix Corporation
  • 12.6 GE HealthCare
  • 12.7 U.S. Preventive Medicine, Inc.
  • 12.8 Siemens Healthineers
  • 12.9 Cancer Prevention Pharmaceuticals
  • 12.10 Johnson & Johnson
  • 12.11 Preventive Medical Health Care
  • 12.12 Abbott Laboratories
  • 12.13 Phoenix Medicine
  • 12.14 F. Hoffmann-La Roche Ltd
  • 12.15 Pfizer Inc.
  • 12.16 Sanofi
  • 12.17 Merck & Co., Inc.

List of Tables

  • Table 1 Global Preventive Medicine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Preventive Medicine Market Outlook, By Service Type (2024-2032) ($MN)
  • Table 3 Global Preventive Medicine Market Outlook, By Health Screenings & Risk Assessments (2024-2032) ($MN)
  • Table 4 Global Preventive Medicine Market Outlook, By Immunization & Vaccination Services (2024-2032) ($MN)
  • Table 5 Global Preventive Medicine Market Outlook, By Lifestyle & Wellness Programs (2024-2032) ($MN)
  • Table 6 Global Preventive Medicine Market Outlook, By Genetic Testing & Personalized Medicine (2024-2032) ($MN)
  • Table 7 Global Preventive Medicine Market Outlook, By Digital Preventive Solutions (2024-2032) ($MN)
  • Table 8 Global Preventive Medicine Market Outlook, By Other Service Types (2024-2032) ($MN)
  • Table 9 Global Preventive Medicine Market Outlook, By Technology (2024-2032) ($MN)
  • Table 10 Global Preventive Medicine Market Outlook, By Early Detection & Screening Technologies (2024-2032) ($MN)
  • Table 11 Global Preventive Medicine Market Outlook, By Remote Monitoring Devices (2024-2032) ($MN)
  • Table 12 Global Preventive Medicine Market Outlook, By Chronic Disease Management Platforms (2024-2032) ($MN)
  • Table 13 Global Preventive Medicine Market Outlook, By Predictive Analytics & AI Tools (2024-2032) ($MN)
  • Table 14 Global Preventive Medicine Market Outlook, By Mode of Delivery (2024-2032) ($MN)
  • Table 15 Global Preventive Medicine Market Outlook, By In-Person Services (2024-2032) ($MN)
  • Table 16 Global Preventive Medicine Market Outlook, By Telemedicine & Remote Care Services (2024-2032) ($MN)
  • Table 17 Global Preventive Medicine Market Outlook, By Mobile Health Applications (2024-2032) ($MN)
  • Table 18 Global Preventive Medicine Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Preventive Medicine Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 20 Global Preventive Medicine Market Outlook, By Cancer (2024-2032) ($MN)
  • Table 21 Global Preventive Medicine Market Outlook, By Diabetes (2024-2032) ($MN)
  • Table 22 Global Preventive Medicine Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 23 Global Preventive Medicine Market Outlook, By Respiratory Diseases (2024-2032) ($MN)
  • Table 24 Global Preventive Medicine Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 25 Global Preventive Medicine Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global Preventive Medicine Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Preventive Medicine Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 28 Global Preventive Medicine Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 29 Global Preventive Medicine Market Outlook, By Corporate & Workplace Wellness Providers (2024-2032) ($MN)
  • Table 30 Global Preventive Medicine Market Outlook, By Home Healthcare (2024-2032) ($MN)
  • Table 31 Global Preventive Medicine Market Outlook, By Government & Public Health Agencies (2024-2032) ($MN)
  • Table 32 Global Preventive Medicine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.